<DOC>
	<DOC>NCT00604760</DOC>
	<brief_summary>To establish the proof of concept that MEM 3454, used as add-on pharmacotherapy, is a safe and effective treatment in patients with cognitive impairment associated with schizophrenia (CIAS).</brief_summary>
	<brief_title>Study to Evaluate the Safety and Efficacy of MEM 3454 as Adjunctive Treatment in Combination With a Preexisting Antipsychotic in Patients With Cognitive Impairment Associated With Schizophrenia</brief_title>
	<detailed_description />
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Cognition Disorders</mesh_term>
	<mesh_term>Antipsychotic Agents</mesh_term>
	<criteria>Diagnosis of schizophrenia (any subtype), assessed using a structured interview. At least one month on the same dose of antipsychotic medication. Clinically stable, as judged by the investigator, and in a nonacute phase for at least 12 weeks. Able to provide informed consent. Fluent in English. Smokers and nonsmokers. First 3 years of schizophrenia diagnosis. Current risk of suicide, or history of suicidal behavior within the last 6 months. Hospitalized for psychiatric symptoms in the past 3 months. Other psychiatric diagnoses. Substance abuse/dependence (other than nicotine or caffeine) within the last 6 months according. Nicotine replacement therapy, smoking cessation medications or remedies, including Varenicline (Chantix).</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>December 2008</verification_date>
</DOC>